Japan Chemical Daily

Japan's leading chemical industry newspaper

Log In

Asahi Kasei Works on New iPS Treatments for Orthopedic Sector

Filed Under: Pharma

Asahi Kasei Corp. (TYO:3407) is bolstering its R&D efforts for regenerative medicine products that use induced pluripotent stem (iPS) cells,…...

Please subscribe to read the full story.

Subscribe Free Trial

Related Articles:

Asahi Kasei Turns Focus to Next-Gen Technologies
Asahi Kasei Turns Focus to Next-Gen Technologies
Keio University Venture Looks to Achieve Breakthrough in Cardiovascular Regenerative Medicine
Keio University Venture Looks to Achieve Breakthrough in…
LSII to Launch Clinical Trials of Muse Cells to Treat Respiratory Failure in COVID-19 Patients
LSII to Launch Clinical Trials of Muse Cells to Treat…
Asahi Kasei Confirms Deep-UV LEDs Can Inactivate COVID-19
Asahi Kasei Confirms Deep-UV LEDs Can Inactivate COVID-19
Asahi Kasei Pursues M&A to Grow Pharmaceuticals Business in Europe
Asahi Kasei Pursues M&A to Grow Pharmaceuticals Business…
Kyoto University Venture Thyas Uses iPS Cells to Generate Killer T Cells for Cancer Treatment
Kyoto University Venture Thyas Uses iPS Cells to Generate…